LGND: Ligand Pharma Company Value to Net Income

Corporate emblem and logo of Ligand Pharmaceuticals Incorporated (LGND)

A steady stream of licensing payments and patent protection create significant defensive barriers for Ligand Pharmaceuticals (LGND). The company's P/E valuation clearly demonstrates the competition for promising molecules amid tight capital conditions, where the current status equals 116.00. Such a pragmatic approach to royalties ensures a professional brand image and mitigates investment risks.

LGND Ligand Corp: Price to Earnings Ratio in the range 07/04/2022 - 11/17/2026

Comprehensive metric breakdowns and analytics for Ligand Pharmaceuticals Incorporated (LGND)

- price and consensus price forecast:
- market capitalization information:
Comprehensive company analysis:Ligand Pharmaceuticals Incorporated - LGND
Flagship merchandise of Ligand

The P/E ratio reflects the market value of a single unit of net profit, allowing an investor to determine the investment payback period and the degree of asset overvaluation. By analyzing changes in the P/E value of Ligand Pharmaceuticals (LGND), one can assess the stability of Ligand Pharmaceuticals, whose royalty-based model minimizes operating expenses and makes cash flow more predictable compared to traditional pharmaceuticals.

Analysis of competing companies

HLN: Company Value to Net Income|Price to Earnings Ratio KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Limited MENS|Amneal (AMRX) - Market Cap to Earnings|PRGO: Price to Earnings Ratio|Alvotech SA - Market Price to Net Income Ratio|LQDA: P/E Multiple|Galapagos Genomics - Company Value to Net Income|ANIP (ANI Pharmaceuticals Inc) - P/E Multiple|Market Cap to Earnings mannkindcorp.com MNKD|Price to Earnings Ratio Amphastar Pharmaceuticals, Inc. (AMPH)|PCRX (Pacira Pharmaceuticals) - Company Value to Net Income|P/E Multiple SPRY (ARS Pharmaceuticals Inc)|Market Price to Net Income Ratio TBPH (Theravance)|AQST - Price to Earnings Ratio|scPharmaceuticals (SCPH) - Price to Earnings Ratio|TECX: P/E Multiple|Price to Earnings Multiple TNXP|Price to Earnings Ratio China SXT Pharmaceuticals, Inc.|EPRX: Company Value to Net Income|P/E Multiple BHST|EXOZ - Market Cap to Earnings|P/E Multiple ORMP (oramed.com)|P/E Multiple enterabio.com ENTX|HYFT - Price to Earnings Ratio|Business Payback Period ABVC BioPharma, Inc ABVC|CPIX: P/E Multiple|Quantum BioPharma Ltd - Company Value to Net Income|Price to Earnings Ratio FGEN|Telomir Pharmaceuticals, Inc. - Market Cap to Net Income|P/E Multiple RANI|SNYR (Synergy CHC) - Company Value to Net Income|Price to Earnings Ratio Rallybio RLYB|Lexaria Bioscience (LEXX) - Market Cap to Earnings|PULM - Price to Earnings Ratio|Business Payback Period Pheton Holdings PTHL|APM (Aptorum) - Price to Earnings Ratio|Lyra Therapeutics, Inc. (LYRA) - P/E Multiple|IBO (impactbiomedinc.com) - P/E Multiple|TNFA (TNF Pharmaceuticals) - Market Price to Net Income Ratio|Price to Earnings Ratio cbdmd.com (YCBD)|Business Payback Period PainReform Ltd|P/E Multiple CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Market Cap to Earnings|OPTN - Price to Earnings Ratio|Pieris Pharmaceuticals - Market Price to Net Income Ratio|PROC (Procaps Group) - Price to Earnings Ratio|PTPI - Business Payback Period|Price to Earnings Ratio Qilian International Holding Group Limited|SLRN: Company Value to Net Income|Price to Earnings Ratio TFFP (TFF Pharma)